GSK settles another Zantac litigation case

GSK plc (LSE/NYSE) has confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court.

The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.

GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

You might also enjoy reading GSK’s Shingrix Prefilled Syringe Approved in Europe

Written by: Amilia Stone

Latest Company News

GSK receives EU approval for Nucala in Eosinophilic COPD

February 6, 2026

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils.

GSK reports strong 2025 results and reaffirms long-term growth outlook

February 4, 2026

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV.

EU approves GSK’s Arexvy RSV vaccine for adults 18+

January 26, 2026

GSK plc announced that the European Commission has approved its RSV vaccine, Arexvy, for use in adults aged 18 years and older.

GSK’s Shingrix Prefilled Syringe Approved in Europe

January 7, 2026

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine.

GSK Plc receives China approval for Nucala in COPD treatment

January 5, 2026

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils.

GSK Plc reaches US agreement to reduce prescription medicine costs

December 22, 2025

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD.